Priapism: Causes, Types, Emergency Treatment, and Long-Term Management

What Exactly Is Priapism?

Priapism is an erection that persists beyond four hours without sexual stimulation, or that does not resolve after orgasm. Blood becomes trapped in the corpora cavernosa, creating a compartment-syndrome physiology identical to what occurs in a compressed limb. The three recognized subtypes are ischemic (low-flow), nonischemic (high-flow), and stuttering (recurrent). Each has a different mechanism, a different treatment algorithm, and a different prognosis for future erectile function.

Prevalence estimates vary by population. In the general U.S. male population, the incidence of priapism is approximately 1.5 per 100,000 person-years, but that figure climbs sharply in men with sickle cell disease, where lifetime risk approaches 42% and a first episode typically occurs before age 20 [1]. A 2020 review in the Journal of Sexual Medicine confirmed that sickle cell disease accounts for roughly one-third of adult ischemic priapism cases presenting to emergency departments in the United States [2].

Because priapism is classified as a urologic emergency under American Urological Association guidance, every clinician treating men's sexual health needs a clear protocol for triage, type differentiation, and escalating intervention [3].

Ischemic vs. Nonischemic Priapism: How to Tell Them Apart

Distinguishing ischemic from nonischemic priapism changes treatment immediately. Ischemic priapism is almost always painful, the penis is fully rigid, and cavernosal blood gas shows acidosis and hypoxia (pO2 <30 mmHg, pCO2 >60 mmHg, pH <7.25). Nonischemic priapism is usually painless, the penis is partially tumescent rather than fully rigid, and it typically follows perineal or penile trauma that creates an arteriovenous fistula with high arterial inflow [4].

Corporal blood gas measurement is the diagnostic gold standard. Color duplex ultrasound of the cavernous arteries adds confirmatory data: absent or minimal flow indicates ischemia, while turbulent high-flow signals a fistula consistent with nonischemic disease [5]. MRI can detect early necrosis of smooth muscle when the diagnosis is still uncertain after several days, but it is rarely practical in the acute setting.

Stuttering priapism occupies a third category. These are recurrent self-limited episodes that each resolve in under four hours, usually during sleep. The pathophysiology overlaps with ischemic priapism because the same venous stasis mechanism is at work, just less severe per episode. Over time, repeated stuttering episodes cause cumulative fibrosis that may progress to permanent erectile dysfunction [6].

Who Gets Priapism? Risk Factors and Causes

Several well-documented mechanisms produce priapism, and identifying the specific trigger guides both acute treatment and long-term prevention.

Hematologic disorders. Sickle cell disease is the leading cause in men under 40. Red cell sickling obstructs venous outflow from the corpora, producing ischemia. Glucose-6-phosphate dehydrogenase deficiency, thalassemia, and leukemia also appear in case series [7]. A 2021 PubMed-indexed cohort study of 247 men with sickle cell disease found that 29% had experienced at least one priapism episode by age 18 [8].

Medications. Intracavernosal vasoactive agents used to treat erectile dysfunction, including alprostadil (prostaglandin E1), papaverine, and phentolamine, carry a quoted priapism rate of 1 to 15% depending on dose and formulation [9]. Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil) cause priapism less often but are not risk-free, particularly at higher doses or in men with concurrent sickle cell disease. Antipsychotics with strong alpha-1-blocking activity, especially trazodone and chlorpromazine, are well-established culprits [10]. Anticoagulants such as heparin and warfarin appear in case reports, likely by impairing the normal clotting that terminates an erection.

Recreational substances. Cocaine and marijuana both appear in emergency-department case series as priapism triggers. Cocaine's alpha-adrenergic effects are paradoxically pro-erectile under certain dose conditions, and cannabis may alter nitric-oxide signaling in cavernosal smooth muscle [11].

Neurologic injury. Spinal cord injury and cauda equina compression can produce nonischemic priapism by disrupting the sympathetic outflow that normally terminates erections.

Idiopathic. In approximately 30 to 40% of cases, no clear cause is identified even after thorough workup [3].

Emergency Treatment: The First Six Hours Matter Most

The window for preserving erectile function is narrow. Smooth muscle necrosis begins as early as four to six hours after the onset of ischemic priapism, and after 24 hours of untreated ischemia, permanent erectile dysfunction occurs in up to 90% of men [12].

The American Urological Association's 2021 Erectile Dysfunction guideline and the EAU Priapism Guidelines both recommend a stepwise approach [3][13]:

Step 1: Corporal aspiration. A 19- or 21-gauge butterfly needle is inserted into one corpus cavernosum at the 2 o'clock or 10 o'clock position to aspirate 20 to 30 mL of dark, hypoxic blood. Aspiration alone resolves approximately 30% of acute ischemic episodes.

Step 2: Intracavernosal phenylephrine. If aspiration alone is insufficient, phenylephrine (a selective alpha-1 adrenergic agonist) is injected at 100 to 500 mcg diluted in normal saline, repeated every three to five minutes up to a maximum of 1 to 000 mcg over one hour. Phenylephrine is preferred over epinephrine because it causes less systemic cardiovascular stimulation. Blood pressure monitoring during injection is standard because hypertensive surges can occur, particularly in older men [13].

Step 3: Surgical shunting. When aspiration plus phenylephrine fails, a distal cavernosal-glanular shunt (Winter shunt or Al-Ghorab shunt) creates outflow for the trapped blood. Proximal shunts (Quackels or Sacher) are reserved for refractory cases. A 2019 systematic review in European Urology found that surgical shunting resolved priapism in 74% of cases where medical treatment had failed, though post-shunt erectile dysfunction rates remained high when the episode had already exceeded 36 hours [14].

Step 4: Penile prosthesis. Early implantation of a penile prosthesis, within days of a refractory episode, has gained traction in recent literature. A 2022 cohort study (N=58) published in Journal of Urology reported that early prosthesis placement was associated with better device outcomes and patient satisfaction compared to delayed implantation after fibrosis had set in [15].

Nonischemic Priapism: A Different Protocol

Nonischemic priapism does not cause ischemia, so it is not an emergency in the same sense. The penis remains semi-rigid, the man is not in pain, and there is no risk of acute smooth muscle necrosis. Treatment is therefore less urgent, and observation alone is appropriate for initial management because spontaneous resolution occurs in up to 62% of cases [16].

When the fistula does not close spontaneously, selective arterial embolization by an interventional radiologist is the preferred approach. Autologous blood clot or absorbable gelatin sponge (Gelfoam) achieves resolution while minimizing the risk of permanent ischemia to the remaining cavernosal tissue. A 2018 meta-analysis in BJUI covering 233 patients reported an overall success rate of 89% with first embolization and retained erectile function in 78% of cases [17].

Surgical ligation of the fistula is reserved for embolization failures and carries a higher erectile dysfunction risk.

Stuttering Priapism: Prevention and Long-Term Management

Stuttering priapism demands a prevention strategy because each episode, even when brief, causes cumulative microtrauma to cavernosal smooth muscle. Several agents are used off-label to reduce episode frequency and severity.

Hormonal suppression. Reducing circulating testosterone attenuates the central erectile drive that contributes to nocturnal episodes. Leuprolide acetate (a GnRH agonist) and bicalutamide (an androgen receptor antagonist) have both been reported in small series to reduce stuttering frequency by 60 to 80%, though long-term androgen suppression carries its own side-effect burden including bone density loss and mood changes [18].

Phosphodiesterase-5 inhibitors at low dose. Counter-intuitively, low-dose daily tadalafil 5 mg has been proposed for stuttering priapism in sickle cell patients. The proposed mechanism is prevention of reperfusion injury by maintaining baseline smooth muscle relaxation between ischemic episodes. A 2017 case series in Urology (N=14) reported a 71% reduction in episode frequency [19].

Digoxin and hydroxyurea. In sickle cell patients, hydroxyurea reduces sickling frequency and has been associated with lower priapism rates in observational data [20]. Its benefit on priapism is considered secondary to its broader disease-modifying effect.

Baclofen. This GABA-B agonist, typically used for spasticity, has appeared in case reports as a nocturnal stuttering-priapism suppressant, though controlled data are absent.

The HealthRX clinical team uses a tiered decision framework for men presenting with recurrent stuttering priapism. Tier 1 addresses any identifiable reversible cause (medication adjustment, sickle cell optimization). Tier 2 introduces low-dose daily tadalafil 5 mg for four to eight weeks with episode diary tracking. Tier 3, reserved for men with more than two episodes per month despite Tier 2 management, adds off-label hormonal suppression under close endocrine monitoring. Tier 4 refers to urology for evaluation of early penile implant candidacy when fibrosis has already begun on MRI.

Priapism and Erectile Dysfunction: Understanding the Link

Priapism and erectile dysfunction are connected in two directions. First, priapism causes erectile dysfunction: the hypoxic damage to cavernosal smooth muscle during ischemic episodes is replaced by collagen and fibrous tissue, eliminating the elastic compliance needed for erection. The longer the episode, the worse the prognosis. One prospective study of 72 men treated for ischemic priapism found that 35% developed clinically significant erectile dysfunction within 12 months regardless of successful detumescence [21].

Second, some ED treatments cause priapism. Intracavernosal injection therapy with alprostadil is the most common iatrogenic cause seen in telehealth-adjacent urology practice. Men starting self-injection programs need specific dose titration protocols and clear instructions to present to the emergency department if erection persists beyond two hours.

Low testosterone is a separate pathway. Hypogonadism contributes to erectile dysfunction through reduced nitric oxide synthase activity in cavernosal tissue, but it is not a direct cause of priapism. When testosterone replacement therapy (TRT) is initiated in a hypogonadal man, the restoration of erectile function may occasionally unmask previously subclinical vascular pathology. Men with sickle cell disease on TRT require particularly close monitoring given the dual risk [22].

Priapism in the Context of GLP-1 and Weight-Loss Therapies

No direct causal link between GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) and priapism has been established in clinical trials or FDA pharmacovigilance data to date. The STEP-1 trial (N=1,961) of semaglutide 2.4 mg reported 14.9% mean weight loss at 68 weeks versus 2.4% placebo, with no priapism events in the safety dataset [23]. Weight reduction improves endothelial function and reduces the cardiovascular risk load that contributes to erectile dysfunction, so GLP-1 therapy may indirectly benefit men with weight-related sexual health concerns. Any man on a GLP-1 agent who develops a prolonged erection should be evaluated for other causes rather than attributing it to the medication without investigation.

When to See a Doctor and What to Expect

Any erection lasting more than two hours that is not subsiding should prompt a call to a medical provider. An erection exceeding four hours is a visit to the emergency department, not a telehealth consult. The clinical workup will include a focused history (onset time, pain level, prior episodes, medication list, sickle cell status), physical exam, cavernosal blood gas, and color duplex ultrasound when the diagnosis is unclear.

After an acute episode resolves, follow-up with a urologist or men's health specialist within two to four weeks is appropriate to assess baseline erectile function, identify the underlying cause, and establish a prevention plan for recurrence. The Sexual Medicine Society of North America (SMSNA) recommends that any man with priapism lasting more than six hours undergo formal erectile function assessment at three months using a validated tool such as the IIEF-5 [24].

Men who develop erectile dysfunction after priapism have multiple evidence-based options: PDE5 inhibitors as first-line pharmacotherapy, vacuum erection devices, low-intensity shockwave therapy, and penile implant surgery for refractory cases. The choice depends on the degree of residual erectile tissue viability determined by penile duplex ultrasound at rest and after intracavernosal injection.